A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

565

Participants

Timeline

Start Date

January 25, 2022

Primary Completion Date

April 11, 2023

Study Completion Date

April 17, 2023

Conditions
Blood Pressure
Interventions
DRUG

VI-0521

Phentermine/Topiramate Top Dose 15 mg/92 mg capsule

DRUG

Phentermine

Phentermine 30 mg capsule

DRUG

Placebo

Inactive oral capsule

Trial Locations (28)

20011

Clinical Site, Washington D.C.

23227

Clinical Site, Port Orange

23502

Clinical Site, Norfolk

27518

Clinical Site, Cary

29223

Clinical Site, Columbia

33134

Clinical Site, Coral Gables

33155

Clinical Site, Miami

36207

Clinical Site, Anniston

36608

Clinical Site, Mobile

37920

Clinical Site, Knoxville

40213

Clinical Site, Louisville

40509

Clinical Site, Lexington

46112

Clinical Site, Brownsburg

47714

Clinical Site, Evansville

59701

Clinical Site, Butte

64114

Clinical Site, Kansas City

67207

Clinical Site, Wichita

70808

Clinical Site, Baton Rouge

76180

Clinical Site, North Richland Hills

77546

Clinical Site, Friendswood

78215

Clinical Site, San Antonio

84124

Clinical site, Salt Lake City

90806

Clinical Site, Long Beach

91786

Clinical Site, Upland

91978

Clinical Site, Spring Valley

95648

Clinical Site, Lincoln

95821

Clinical Site, Sacramento

97404

Clinical Site, Eugene

All Listed Sponsors
lead

VIVUS LLC

INDUSTRY